Treace Medical Concepts, Inc.

Equities

TMCI

US89455T1097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
8.45 ^USD	+2.80%		+25.19%	-33.73%

16/07	Truist Raises Price Target on Treace Medical Concepts to $9 From $7, Maintains Hold Rating	MT
15/07	Morgan Stanley Raises Price Target on Treace Medical Concepts to $8 From $5.50, Keeps Equalweight Rating	MT

Treace Medical Concepts, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022

January 09, 2023 at 06:30 pm IST

Treace Medical Concepts, Inc. provided revenue guidance for the fourth quarter of 2022. For the quarter, the company revenue anticipated to be in the range of $49.1 to $49.6 million, representing an increase in the range of 47% to 48%.

Latest news about Treace Medical Concepts, Inc.

Truist Raises Price Target on Treace Medical Concepts to $9 From $7, Maintains Hold Rating	16/07	MT
Morgan Stanley Raises Price Target on Treace Medical Concepts to $8 From $5.50, Keeps Equalweight Rating	15/07	MT
Treace Medical Concepts, Inc.(NasdaqGS:TMCI) dropped from S&P Healthcare Equipment Select Industry Index	24/06	CI
Treace Medical Concepts Insider Bought Shares Worth $253,475, According to a Recent SEC Filing	30/05	MT
North American Morning Briefing : The "Everything -2-	17/05	DJ
UBS Downgrades Treace Medical Concepts to Neutral From Buy, Cuts Price Target to $6.50 From $16	16/05	MT
Transcript : Treace Medical Concepts, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 02:20 PM	16/05
Top Midday Decliners	09/05	MT
UBS Adjusts Price Target on Treace Medical Concepts to $16 From $17, Maintains Buy Rating	08/05	MT
Truist Downgrades Treace Medical Concepts to Hold From Buy, Cuts PT to $7 From $17; Notes Slowing Growth Outlook Amid Rising Competitive Pressures	08/05	MT
Top Premarket Decliners	08/05	MT
Truist Securities Downgrades Treace Medical Concepts to Hold From Buy, Lowers Price Target to $7 From $17	08/05	MT
BTIG Downgrades Treace Medical Concepts to Neutral From Buy	08/05	MT
JPMorgan Downgrades Treace Medical Concepts to Neutral From Overweight, Cuts Price Target to $8 From $15	08/05	MT
Stifel Downgrades Treace Medical Concepts to Hold From Buy, Cuts Price Target to $6 From $15	08/05	MT
Treace Medical Concepts Falls 57% Premarket After Revising 2024 Sales Outlook to $201-$211 Million From $220-$225 Million	08/05	MT
Earnings Flash (TMCI) TREACE MEDICAL CONCEPTS Reports Q1 Revenue $51.1M, vs. Street Est of $49.1M	08/05	MT
Transcript : Treace Medical Concepts, Inc., Q1 2024 Earnings Call, May 07, 2024	08/05
Treace Medical Concepts, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Treace Medical Concepts, Inc. Revises Earnings Guidance for the Full-Year 2024	08/05	CI
Treace Medical Concepts Treats 100,000 Patients With Lapiplasty Bunion Correction	25/03	MT
Transcript : Treace Medical Concepts, Inc., Q4 2023 Earnings Call, Feb 27, 2024	28/02
Treace Medical Concepts, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Earnings Flash (TMCI) TREACE MEDICAL CONCEPTS Reports Q4 Revenue $62.2M, vs. Street Est of $60.2M	28/02	MT
Treace Medical Concepts, Inc. Provides Revenue Guidance for the Year 2024	28/02	CI

Chart Treace Medical Concepts, Inc.

Duration

Period

More charts

Company Profile

Treace Medical Concepts, Inc. is a medical technology company. The Company is focused on advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It also has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of the midfoot as well as its Hammertoe PEEK Fixation System designed to address hammertoe, claw toe and mallet toe deformities. The Lapiplasty, Adductoplasty and Hammertoe PEEK Fixation Systems are comprised of single-use implant kits and reusable instrument trays. The Company sells these products to physicians, surgeons, hospitals and ambulatory surgery centers in the United States.

Sector

Medical Equipment, Supplies & Distribution

Calendar

06/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Treace Medical Concepts, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

8.45 USD

Average target price

7.583 USD

Spread / Average Target

-10.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Equipment

	1st Jan change	Capi.
TREACE MEDICAL CONCEPTS, INC.	-33.73%	524M
SHOCKWAVE MEDICAL	+75.69%	12.57B
PENUMBRA, INC.	-21.78%	7.63B
MASIMO CORPORATION	-6.25%	5.84B
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.	+8.16%	5.16B
GETINGE AB	-17.97%	4.75B
APT MEDICAL INC.	+16.22%	4.16B
ASAHI INTECC CO., LTD.	-12.24%	4.17B
INARI MEDICAL, INC.	-10.69%	3.37B
SKAN GROUP AG	-2.72%	1.99B

Medical Equipment